Artificial Intelligence in Personalized Medicine, Genomic Sequencing Advances, Human Brain Organogenesis, Building Trust with Patients, Guiding Patient Decisions with Mass Spectrometry, and Much More to Be Explored at the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo – QNT Press Release

[ad_1]

CHICAGO, July 24, 2022 /PRNewswire/ — At the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo, laboratory medicine experts will present the cutting-edge research and technology that is revolutionizing clinical testing and patient care. From July 24-28 in Chicagothe meeting’s 250-plus sessions will deliver insights on a broad range of timely healthcare topics. Highlights include discussions exploring the use of artificial intelligence (AI) in personalized medicine, advances in multiplexed genomic sequencing and imaging, real-life applications of human brain organogenesis, how to build trust with patients, and guiding clinical decisions with mass spectrometry.

AI in Personalized Medicine. Precision medicine involves tailoring treatments to individual patients and, increasingly, clinicians are using AI in their clinical prediction models to do this. In the meeting’s opening keynote, Dr. Lucila Ohno-Machadohealth associate dean of informatics and technology at the University of California San Diegowill introduce how AI models are developed, tested, and validated as well as performance measures that may help clinicians select these models for routine use.

Multiplexed Genomic Sequencing and Imaging. Thanks to advances in multiplexed genomic sequencing and imaging, we can identify small but crucial differences in DNA, RNA, proteins, and more. These techniques have also undergone a 50-million-fold reduction in cost and comparable improvements in quality since they first emerged . In spite of this, healthcare is just beginning to catch up with the implications of these technologies. Dr. George ChurchAACC’s 2022 Wallace H. Coulter Lectureship Awardee and founding core faculty and lead at the Synthetic Biology …

Full story available on Benzinga.com

[ad_2]

Source link